- Home
- TRTX vs TRVI Comparison
TRTX vs TRVI Comparison
Compare TRTX & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRTX
- TRVI
- Stock Information
- Founded
- TRTX 2014
- TRVI 2011
- Country
- TRTX United States
- TRVI United States
- Employees
- TRTX N/A
- TRVI N/A
- Industry
- TRTX Real Estate Investment Trusts
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- TRTX Real Estate
- TRVI Health Care
- Exchange
- TRTX Nasdaq
- TRVI Nasdaq
- Market Cap
- TRTX 632.5M
- TRVI 725.7M
- IPO Year
- TRTX 2017
- TRVI 2019
- Fundamental
- Price
- TRTX $8.16
- TRVI $5.88
- Analyst Decision
- TRTX Strong Buy
- TRVI Strong Buy
- Analyst Count
- TRTX 4
- TRVI 9
- Target Price
- TRTX $9.50
- TRVI $19.94
- AVG Volume (30 Days)
- TRTX 723.8K
- TRVI 2.2M
- Earning Date
- TRTX 07-29-2025
- TRVI 08-07-2025
- Dividend Yield
- TRTX 11.93%
- TRVI N/A
- EPS Growth
- TRTX N/A
- TRVI N/A
- EPS
- TRTX 0.70
- TRVI N/A
- Revenue
- TRTX $148,005,000.00
- TRVI N/A
- Revenue This Year
- TRTX N/A
- TRVI N/A
- Revenue Next Year
- TRTX $9.19
- TRVI N/A
- P/E Ratio
- TRTX $11.52
- TRVI N/A
- Revenue Growth
- TRTX N/A
- TRVI N/A
- 52 Week Low
- TRTX $6.47
- TRVI $2.36
- 52 Week High
- TRTX $9.66
- TRVI $7.48
- Technical
- Relative Strength Index (RSI)
- TRTX 58.41
- TRVI 48.75
- Support Level
- TRTX $7.63
- TRVI $5.41
- Resistance Level
- TRTX $8.03
- TRVI $5.96
- Average True Range (ATR)
- TRTX 0.15
- TRVI 0.30
- MACD
- TRTX -0.01
- TRVI -0.03
- Stochastic Oscillator
- TRTX 91.09
- TRVI 53.02
About TRTX TPG RE Finance Trust Inc.
TPG RE Finance Trust Inc is a commercial real estate finance company. It originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments consisting of first mortgage loans and senior participation interests in first mortgage loans secured by institutional-quality properties in primary and select secondary markets in the United States. The company's objective is to provide attractive risk-adjusted returns to its stockholders over time through cash distributions and capital appreciation. It focuses on directly originating and selectively acquiring floating rate first mortgage loans that are secured by high quality commercial real estate properties undergoing some form of transition and value creation.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.